News & Views
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at…
Read more
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6…
Read more
Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT…
Read more
Telix Pharmaceuticals Limited is pleased to provide its Annual Report…
Read more
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical…
Read more
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)…
Read more
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January…
Read more
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical…
Read more
News,
Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market…
Read more